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Denver Nephrologists, Denver, Colorado
The impact of calcimimetics on mineral metabolism and sec-
ondary hyperparathyroidism in end-stage renal disease. Sec-
ondary hyperparathyroidism is often complicated by elevations
in calcium and phosphorus either as a result of the disease per
se or due to toxicity from current therapeutic options. These
disturbances in mineral metabolism limit the successfulness
of therapy and have been implicated as contributing to the
development and progression of vascular calcification, an im-
portant and often overlooked component of cardiovascular
disease in patients on dialysis.
Phosphorus, active vitamin D, and calcium all play important
roles in the pathogenesis of secondary hyperparathyroidism;
however, serum calcium is the primary regulator of minute-
to-minute parathyroid hormone secretion. Small changes in
serum calcium are detected by a cell surface calcium sensing
receptor that has recently been cloned. Calcimimetic agents
modulate the activity of the calcium-sensing receptor and result
in profound reductions in levels of circulating parathyroid hor-
mone. Additionally, these agents result in decreases in serum
calcium, phosphorus, and calcium-phosphorus product. Re-
cently completed phase 2 clinical trials with the second-genera-
tion calcimimetic agent cinacalcet HCl confirm that this agent
represents a safe and effective novel therapeutic agent which
has the potential to dramatically alter the treatment and com-
plications associated with secondary hyperparathyroidism in
patients on dialysis.
Secondary hyperparathyroidism begins early in the
course of chronic kidney disease and is characterized
by progressive parathyroid gland hyperplasia, excessive
parathyroid hormone secretion, and abnormalities in cal-
cium and phosphorus metabolism. Untreated, the dis-
ease ultimately affects the majority of patients with stage
5 chronic kidney disease, leading to significant skeletal
and extraskeletal toxicity.
Traditional treatment of secondary hyperparathyroid-
ism (SHPT) generally includes dietary modification,
phosphate binders, and vitamin D sterols. Increases in
serum calcium and/or phosphorus either as a result of the
treatment regimen or from the disease itself are frequent
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enough to preclude continuous, effective therapy and
may increase the risk of cardiovascular morbidity and
mortality. Consequently, clinicians often choose between
the untoward effects of available treatment options and
the toxicity of inadequately treated SHPT. Forthcoming
national recommendations for more stringent control
of calcium, phosphorus, calcium  phosphorus product
(Ca  P), parathyroid hormone, and exposure to ele-
mental calcium will further challenge the management
of this systemic disease.
The primary function of the parathyroid gland is main-
tenance of serum calcium and it is the extracellular cal-
cium concentration, acting via the calcium-sensing re-
ceptor (CasR), which is the key regulator of parathyroid
hormone secretion [1]. Calcimimetic agents represent a
new class of small organic molecules that mimic the action
of calcium on the CasR. Cinacalcet HCl is a second gener-
ation, type II calcimimetic agent that acts as a positive
allosteric modulator of the CasR, increasing its sensitivity
in the presence of extracellular calcium and resulting in
an abrupt decrease in parathyroid hormone concentration.
Because of their fundamentally different mechanism of
action, calcimimetic agents do not exacerbate disturbances
in calcium and phosphorus homeostasis; rather, they are
associated with clinically meaningful decreases in the
plasma concentrations of these minerals [2].
The development of novel therapeutic agents such
as cinacalcet HCl represents a significant step toward
achieving successful control of SHPT. By favorably im-
pacting calcium and phosphorus homeostasis, cinacalcet
HCl may modify the current natural history of vascular
calcification in dialysis patients. This article will briefly
review the factors responsible for SHPT, the risks of
current therapy with regard to mineral metabolism, and
discuss the pre-clinical and clinical data supporting the
efficacy and safety of calcimimetics for the treatment of
SHPT in patients with end-stage renal disease.
PATHOPHYSIOLOGY OF SHPT
Eight million Americans have an estimated glomeru-
lar filtration rate (eGFR)60 mL/min/1.73 m2 [3]. At this
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Fig. 1. Mechanisms underlying secondary hyperparathyroidism (SHPT).
Calcium is the key regulator of parathyroid hormone (PTH) secretion.
level of kidney function, evidence of impaired calcitriol
production, elevations in serum phosphorus (though still
within the normal range), and progressive elevations in
parathyroid hormone occur [4, 5]. Unfortunately, the
development of SHPT often goes undetected, even when
patients are referred to a nephrologist. A recent analysis
of patients with stage 4 chronic kidney disease seen by
nephrologists found that only 15% were assessed for
levels of parathyroid hormone (iPTH) over a 4-year fol-
low-up period [6].
SHPT is the result of parathyroid gland hyperplasia,
excessive iPTH production, and increased iPTH secre-
tion. Phosphorus, calcium, and active vitamin D levels
affect these events independently and uniquely (Fig. 1)
[7]. Dissociation of parathyroid gland hyperplasia from
iPTH secretion has been described and may occur com-
monly within the context of current management, which
emphasizes treatment rather than prevention [7].
The primary effect of vitamin D is to decrease the
production of pre-pro PTH synthesis, an effect that mani-
fests over a period of hours-days [8]. Phosphorus exerts
a stimulatory effect on chief cell hyperplasia, pre-pro
PTH transcription, PTH mRNA stability, and may also
modulate iPTH secretion [7, 9]. The primary regulator
of iPTH secretion, however, is serum calcium. Minute
changes in extracellular calcium concentration are de-
tected by the CasR, a cell surface G-protein coupled
receptor. Activation of the receptor increases intracellu-
lar calcium concentration and results in an abrupt de-
crease in iPTH secretion [10]. The cloning of the CasR in
1993 and rapid clarification of its role in the parathyroid
gland and kidney represents a remarkable achievement.
Mutations of this receptor are now known to be responsi-
ble for several congenital diseases, including familial hy-
pocalciuric hypercalcemia, and severe neonatal hyper-
parathyroidism [11].
Calcimimetic compounds are small organic molecules
that mimic the effect of calcium on the CasR. Type I
Fig. 2. Contrasting effects of vitamin D and calcimimetic compounds
on the daily pattern of parathyroid hormone (PTH).
agents are polycations, which act as direct agonists bind-
ing to the extracellular portion of the receptor, while
type II agents modulate (increase) the sensitivity of the
receptor to ambient calcium concentration after binding
to the membrane spanning portion of the receptor (Fig.
2) [10]. Nemeth et al [12] first described the ability of
the calcimimetic NPS-R568 to potently and selectively
modulate the activity of the CasR. Numerous pre-clinical
and clinical trials were done with this compound, which
confirmed the ability of NPS-R568 to suppress iPTH in
animal and human models of SHPT [13]. Subsequent
clinical development was abandoned, however, due to
an unfavorable pharmacokinetic profile. More recent
clinical trials have used a second-generation type II calci-
mimetic, cinacalcet HCl (AMG073).
In addition to being the primary regulator of minute-
to-minute iPTH secretion, serum calcium, acting through
the CasR, is also an important regulator of parathyroid
gland hyperplasia and intracellular PTH mRNA stability
[14]. This important role has been demonstrated in vita-
min D receptor and CasR knockout mice and in sub-
totally nephrectomized animal models of SHPT. Mice with
no expression of the vitamin D receptor (VDR) demon-
strate severe SHPT, hypocalcemia, hypophosphatemia,
rickets, and osteomalacia. All of these manifestations,
including the SHPT, can be corrected with the provision
of a diet that normalizes serum calcium [15]. Animals
who lack expression of the CasR demonstrate severe
SHPT despite elevated serum calcium, elevated vita-
min D levels, and normal serum phosphorus [16]. Admin-
istration of NPS-R568 to animals with severe SHPT in-
duced by subtotal nephrectomy was able to prevent the
development of parathyroid gland hyperplasia, halt the
progression of established SHPT, and reverse the skele-
tal effects of SHPT, despite the stimulatory effects of
hyperphosphatemia and reduced active vitamin D levels
[17–19].
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CONSEQUENCES OF SHPT AND
ITS TREATMENT
Excess parathyroid hormone has significant systemic
adverse effects in addition to its well-known skeletal
toxicity. PTH increases cytosolic calcium concentration,
an effect particularly harmful to cardiomyocytes, and
has a permissive role in the development of myocardial
interstitial fibrosis and intramyocardial arteriolar wall
thickening [20, 21]. Recently, researchers have found
that both parathyroidectomy and the administration of
the calcimimetic NPS-R568 were able to markedly im-
prove the structural abnormalities (interstitial fibrosis,
reduced capillary length density, and arteriolar wall
thickness) associated with experimentally induced SHPT
[22]. Serum phosphorus, independent of PTH, also ag-
gravates cardiac fibrosis and ultra-structural abnormali-
ties in animal models of uremia [23].
Perhaps the most difficult challenge in treating SHPT
is related to the fact that complications such hypercalce-
mia, hyperphosphatemia, and an elevated calcium-phos-
phorus ion product (Ca  P) may be a result of the
disease per se or may be a consequence of the currently
available therapeutic choices. Furthermore, treatment
with large doses of calcium-containing phosphate bind-
ers and active vitamin D sterols induces a state of positive
calcium balance and may contribute to over-suppression
of bone turnover and the development of adynamic bone
disease.
There exists a narrow therapeutic window for clini-
cians to achieve a state of normal bone turnover without
inducing abnormalities in mineral metabolism or toxicity
from excessive binder utilization. As a result, therapy is
frequently characterized by intermittent, modestly suc-
cessful treatment alternating with periods of overt toxic-
ity. Not surprisingly, the natural history of SHPT in pa-
tients with stage 5 CKD is one of progressive worsening,
often with years of exposure to both excessive iPTH
levels and poor control of mineral metabolism [24].
This paradigm is particularly intolerable given evi-
dence that hyperphosphatemia, elevated Ca  P, and
the use of moderate-to-large doses of calcium-containing
phosphate binders are associated with cardiovascular
morbidity and mortality. Three large epidemiologic stud-
ies report an independent direct association between
elevated serum phosphorus and mortality [6% to 8%
increase in relative risk (RR) per 1 mg/dL increase in
serum phosphorus] [25–27]. This excess risk appears to
be primarily a result of an increase in cardiovascular
death [25]. Several investigators have also reported an
increased risk of death associated with an elevated CaP,
including a recent report in which patients with a Ca P
64 mg2dL2 were found to have a three-fold increase in
mortality [28].
The mechanism underlying the association between
mineral metabolism and mortality is not fully under-
stood. Current hypotheses suggest that the mortality risk
is related to the development of vascular calcification
and the adverse hemodynamic effects thereof. Jono et al
[29], in a landmark publication, reported that serum
phosphorus was able to induce vascular smooth muscle
cells to calcify their environment in a dose-dependent
fashion. Subsequently, it has become evident that vascu-
lar calcification is an active process involving a wide
variety of stimulatory and inhibitory factors. Moe et al
[30] have recently described the ability of uremic serum,
independent of serum phosphorus, to stimulate the ex-
pression of cbfa-1 by vascular smooth muscle cells. Im-
portantly, these investigators describe a multi-step process
in which expression of bone-related proteins precedes
the development of overt vascular calcification. It is
therefore plausible that abnormalities of mineral metab-
olism affect vascular calcification at multiple steps in the
pathway.
Vascular calcification (VC) may represent calcium ac-
cumulation either in association with intimal atheroscle-
rotic plaque or in the vascular media. It is inappropriate
to consider VC synonymous with “atherosclerotic dis-
ease” in patients with CKD and, by extension, erroneous
to judge the significance of VC by the presence, absence,
or severity of luminal arterial stenosis. The physiologic
consequences are quite distinct between intimal and me-
dial calcification; however, calcium accumulation in ei-
ther location is associated with adverse cardiovascular
outcomes in patients with end-stage renal disease.
Arterial medial calcification unfavorably alters the
cushioning function of the arterial tree. As arterial stiff-
ness increases, distensibility or compliance decreases and
the “windkessel,” or “auxiliary pump” function of the
aorta diminishes. Ultimately, systolic blood pressure in-
creases, diastolic blood pressure diminishes, and pulse
pressure widens. Each of these events produces unfavor-
able effects on left ventricular load and on the cardiac
vascular demand/supply relationship [31]. London et al
[32–35] have documented in hemodialysis patients that
increases in aortic stiffness as assessed by aortic pulse
wave velocity are related to the degree of vascular calci-
fication and are associated with increases in left ventricu-
lar size and with an increased risk of cardiovascular mor-
tality. Arterial calcification induced increases in vascular
stiffness also augment the wave reflectance of the arterial
tree, further augmenting systolic blood pressure and di-
minishing diastolic blood pressure. As pulse pressure
widens, coronary artery perfusion is increasingly com-
promised, particularly in the presence of otherwise “non-
significant” luminal stenosis. A seminal report by Guerin
et al [32] reported that the risk factors for arterial calcifi-
cation in hemodialysis patients included age, duration
of dialysis, fibrinogen, and the dose of calcium containing
binder prescribed. Subsequently, this same group de-
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Fig. 3. Effect of calcimimetic on the sigmoidal Ca2-parathyroid hor-
mone (PTH) relationship. Calcimimetics result in a leftward shift of
the set point, thereby resulting in greater PTH suppression at any level
of ionized calcium.
scribed a striking relationship between the presence or
absence of VC as detected by ultrasound and survival
in hemodialysis patients [35]. These results are consistent
with the recent report by Chertow et al [36], who de-
scribed a significant effect of calcium-containing phos-
phate binders on the progression of established coronary
artery and aortic calcification.
In aggregate, this data suggests that hypercalcemia,
hyperphosphatemia, elevated calcium-phosphorus ion
product, and the requirement for moderate-to-large
doses of calcium-containing phosphate binders likely un-
derlie, in part, the accelerated risk of VC and cardiovas-
cular morbidity and mortality experienced by patients
on hemodialysis. There is no compelling evidence that
VC is reversible, emphasizing the need for prevention
as a primary therapeutic strategy. The implication that
this has for the current treatment strategy is profound.
EFFICACY AND SAFETY OF
CINACALCET HCL
Administration of cinacalcet HCl results in a dose-
dependent fall in iPTH with a nadir occurring at approxi-
mately four hours. Over the next 24 hours, iPTH rises
slowly but remains significantly below baseline at 24
hours post-dose [37]. This results in a cyclical pattern of
iPTH suppression that is quite distinct from that seen
when using vitamin D sterols (Fig. 3) [38]. This difference
between cinacalcet HCl and vitamin D sterols is due
to the fundamentally different mechanism of action of
cinacalcet HCl to control the minute-to-minute secretion
of iPTH and has important clinical implications. Data
suggest that pulsatile changes in iPTH which occur with
the administration of synthetic 1-34 iPTH have a stimula-
tory effect on bone formation and reduces fractures in
osteoporotic females [39]. Similarly, uremic rats with low
turnover bone lesions given intermittent daily doses of
NPS-R568 experienced increases in trabecular bone vol-
ume and bone mineral density, while continuous infusion
of the calcimimetic had no such anabolic effect. Whether
intermittent variations in iPTH associated with cinacal-
cet HCl produces similar effects on bone remodeling in
hemodialysis subjects is under investigation. The pattern
of iPTH suppression also will demand precision on the
part of the healthcare team in evaluating iPTH results
with regard to the time of drug administration. The 24-
hour iPTH will clearly underestimate the actual degree
to which iPTH has been suppressed.
Several double-blind, placebo-controlled, randomized
trials evaluating cinacalcet HCl in patients with inade-
quately controlled SHPT (iPTH 300 pg/mL), despite
standard therapy, have recently been reported. Using
daily doses of cinacalcet HCl up to 50 mg/day, Lindbergh
et al [2] reported a 26% decrease in iPTH in cinacalcet
HCl–treated subjects as compared to a 22% increase in
the placebo group over the evaluation phase of an 18
week trial (P  .001). Cinacalcet HCl treated patients
experienced a 12% fall in the Ca  P (4.7% fall in mean
serum calcium, 7.5% fall in mean serum phosphorus)
during the efficacy assessment phase as compared with
an 11% increase in Ca  P in the placebo group. These
treatment benefits were independent of vitamin D use
(which was similar between the two groups).
Using larger daily doses of cinacalcet HCl (up to 100
mg/day) in a similar study design, Quarles et al report
a 33% decrease in mean iPTH over a 12 week efficacy
assessment phase compared with a 3% increase in pla-
cebo patients (P  .0001). Again, a significant decrease
in Ca P was experienced by the cinacalcet HCl–treated
patients (7.9% vs. 11.3%, P  .013).
We have recently reported the results of a 12-week
double-blind, placebo-controlled randomized trial using
doses of cinacalcet HCl up to 180 mg/day in patients
with an iPTH 300 pg/mL receiving standard therapy
with phosphate binders and/or vitamin D sterols. Base-
line iPTH were similar between the two groups (cinacal-
cet HCl 556 294 pg/mL vs. placebo 630 362 pg/mL).
Sixty-three percent of cinacalcet-treated patients were
able to achieve the primary end point of a mean iPTH
250 pg/mL during the four-week efficacy assessment
phase as compared to 7% of placebo-treated patients
(P .001). The proportion of patients achieving a	30%
reduction in mean iPTH was 74% in cinacalcet-treated
patients versus 11% of placebo treated subjects (P 
.001). Sixty percent of cinacalcet HCl–treated patients
achieved the combined end point of a 	30% reduction
in iPTH and a reduction in Ca  P as compared to
9% of placebo-treated subjects (P  .001). An 8.4%
reduction in serum calcium and 5.3% reduction in phos-
phorus was experienced by the cinacalcet HCl–treated
subjects [abstract; Block et al, J Am Soc Nephrol 13:572A,
2002].
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Fig. 4. Shown is parathyroid hormone (PTH)
suppression achieved with cinacalcet HCl dur-
ing a 2-year trial in which patients were ran-
domized to placebo or cinacalcet (up to 50
mg/day or up to 100 mg/day) during the first
year and subsequently rolled over into open
label therapy with cinacalcet at doses up to
180 mg/day.
These favorable short-term results have been sus-
tained over a two-year period of time. Patients initially
enrolled in two separate one-year randomized placebo-
controlled trials with doses of cinacalcet up to 50 mg/
day or 100 mg/day were then eligible to roll into an open
label extension trial in which doses of cinacalcet HCl
could be titrated to a maximum of 180 mg/day. Results
from this trial are shown in Figure 4. After one year
of open label treatment, 54% of subjects had a 	30%
reduction in iPTH. Treatment with cinacalcet HCl pre-
vented Ca  P levels from increasing over two years
[abstract; Moe SM et al, ASN, 2002].
Cinacalcet HCl was well tolerated in each of these
phase 2 clinical trials. There was a significant increase
in gastrointestinal side effects (nausea, vomiting, abdom-
inal pain) seen with rapid titration of cinacalcet HCl over
an eight-week period to a dose of 180 mg. These side
effects were generally mild to moderate in severity.
Asymptomatic hypocalcemia was experienced by 8% to
17% of patients; however, no patients discontinued the
studies due to low calcium, and serum calcium was nor-
malized with modest changes in phosphate binders
and/or adjustments in vitamin D. No other clinically rele-
vant trends were observed in other laboratory parame-
ters.
CONCLUSION
Current treatment options for SHPT in patients with
end-stage renal disease are often complicated by episodic
hypercalcemia, hyperphosphatemia, and elevations in
Ca  P which limit their efficacy. As a result, clinicians
are often forced to choose between achieving control of
SHPT and producing overt toxicity from disorders of
mineral metabolism. The serious and potentially irre-
versible cardiovascular consequences now thought to be
related to these mineral disturbances mandate a change
in practice patterns. The development of the novel calci-
mimetic agent cinacalcet HCl offers precise control over
iPTH secretion while having a favorable impact on serum
calcium, phosphorus, and Ca  P. Calcimimetic agents
offer the opportunity to modify the heretofor inevitable
development and progression of SHPT and its conse-
quences. Optimistically, this will ultimately affect the
cardiovascular risk of patients with end-stage renal dis-
ease.
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